Feasibility · Alzheimer's · Phase II–III
Alzheimer's disease trial feasibility, cited to its source.
Alzheimer's feasibility is defined by hard-to-reach, biomarker-confirmed populations and notoriously slow screening. Honest feasibility here means surfacing the screen-fail and enrollment-velocity risk explicitly, not just counting prevalent patients.
Deterministic, re-runnable feasibility scoring.
What drives feasibility here
The questions that decide go or no-go.
- Amyloid/tau confirmation (PET or CSF) gates eligibility and slows screening.
- High screen-fail rates make enrollment velocity, not prevalence, the binding constraint.
- Caregiver and site-network requirements limit the viable site list.
- Historically low approval rates warrant conservative, clearly-labelled PTRS priors.
Grounded in public data
For alzheimer's, the verdict draws primarily on ClinicalTrials.gov, AACT, PubMed, FDA, Open Targets — every figure links back to its source record with a snapshot date, so your team and the sponsor can re-verify it. See the full data sources and compare other indications.
See a cited verdict for alzheimer's.
Send us a protocol. We'll return a fully cited feasibility verdict you can trace, line by line, back to public data — yours to white-label, defend in a bid, or hand to a regulator.